Author: Newsdesk

Posted on

Aptima HIV-1 Quant Dx Assay Receives Additional FDA Approval for Use as an Aid in the Diagnosis of HIV Infection

Aptima HIV-1 Quant Dx Assay Receives Additional FDA Approval for Use as an Aid in the Diagnosis of HIV Infection

— First FDA-Approved Assay for Both Qualitative Diagnosis and Quantitative Viral Load Monitoring —

MARLBOROUGH, Mass.–(BUSINESS WIRE)–
Hologic, Inc. (Nasdaq: HOLX) announced today that the U.S. Food and Drug Administration (FDA) has approved a diagnostic claim for its HIV-1 (human immunodeficiency virus type 1) viral load monitoring assay. The Aptima® HIV-1 Quant Dx assay is now the first dual-claim assay for both diagnosis and viral load monitoring in the United States.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201120005242/en/

Aptima® HIV-1 Quant Dx assay (Photo: Business Wire)

Aptima® HIV-1 Quant Dx assay (Photo: Business Wire)

The AptimaHIV-1 Quant Dx assay, which was approved in late 2016 for viral load monitoring, is a molecular diagnostic test that runs on the fully automated, sample-to-result Panther® system. The assay utilizes a dual target approach against highly conserved regions in the HIV genome that is designed to deliver reliable, consistent qualitative and quantitative results across HIV-1 groups and subtypes. The Aptima HIV-1 Quant Dx assay is also CE IVD-marked for both diagnostic and viral load monitoring claims.

“This is an exciting new claim for our highly sensitive and reliable HIV test because it has the potential to improve patient care,” said Kevin Thornal, president of Diagnostic Solutions at Hologic. “A simultaneous viral load measurement with diagnosis will allow healthcare providers to guide treatment choices for patients to begin therapy immediately. The dual claim will also benefit our clinical laboratory customers, who continuously seek to consolidate their testing as much as possible onto one automated platform.”

Starting treatment at the time of diagnosis is expected to reduce the risk of HIV transmission to others and to maximize prospects for long-term good health.

There are approximately 1.2 million people living in the US with HIV, with 38,000 new infections in 2018.1

For more information about Hologic’s U.S. virology portfolio, please visit: http://usaptimavirology.com.

About the Panther and Panther Fusion Systems

The Panther molecular diagnostics system is a best-in-class, fully automated, sample-to-result platform that can be used in low-, medium- or high-throughput laboratories. With a small footprint, adaptable workflow options and consolidated testing menu, it combines women’s health, sexually transmitted infection and viral load testing, which can all be done simultaneously. The Panther Fusion system provides an expanded in vitro diagnostics menu, as well as Open AccessTM functionality to run laboratory developed tests. Hologic’s Panther and Panther Fusion systems now offer 18 FDA-cleared assays and 20 CE-marked assays that detect more than 20 pathogens. More than 2,250 Panther systems have been installed in clinical diagnostic laboratories around the world.

About Hologic

Hologic, Inc. is an innovative medical technology company primarily focused on improving women’s health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com.

Forward-Looking Statements

This press release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic’s diagnostic products. There can be no assurance these products will achieve the benefits described herein or that such benefits will be replicated in any particular manner with respect to an individual patient. The actual effect of the use of the products can only be determined on a case-by-case basis depending on the particular circumstances and patient in question. In addition, there can be no assurance that these products will be commercially successful or achieve any expected level of sales. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such statements are based.

Hologic, The Science of Sure, Aptima and Panther are trademarks and/or registered trademarks of Hologic, Inc. in the United States and/or other countries.

References:

  1. HIV.gov: U.S. Statistics. https://www.hiv.gov/hiv-basics/overview/data-and-trends/statistics. Accessed on 11/12/2020.

SOURCE: Hologic, Inc.

Investor Contact

Michael Watts

Vice President, Investor Relations and Corporate Communications

(858) 410-8588

[email protected]

Media Contact:

Jane Mazur

+1 508.263.8764 (direct)

+1 585.355.5978 (mobile)

[email protected]

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: Infectious Diseases FDA AIDS Health

MEDIA:

Logo
Logo
Photo
Photo
Aptima® HIV-1 Quant Dx assay (Photo: Business Wire)
Posted on

Microchip Technology Incorporated Announces Private Placement of $609 Million Principal Amount of 0.125% Convertible Subordinated Notes Due 2024 and Related Exchange Transactions

CHANDLER, Ariz., Nov. 20, 2020 (GLOBE NEWSWIRE) — (NASDAQ: MCHP) – Microchip Technology Incorporated (“Microchip”) announced that it has entered into privately negotiated exchange agreements with certain holders of its outstanding 1.625% Convertible Senior Subordinated Notes due 2025 (the “2025 Notes”), 1.625% Convertible Senior Notes due 2027 (the “2027 Notes”) and 2.250% Convertible Junior Subordinated Notes due 2037 (the “2037 Notes” and, together with the 2025 Notes and the 2027 Notes, collectively, the “Existing Notes”) pursuant to which Microchip will issue, deliver and pay, as the case may be, an aggregate of (a) $609.0 million principal amount of 0.125% Convertible Subordinated Notes due 2024 (the “New Notes”); (b) a certain number of shares of Microchip’s common stock based on the reference price (as defined below) and (c) approximately $421.0 million in cash, collectively, in exchange for approximately $90.0 million principal amount of the 2025 Notes, approximately $532.3 million principal amount of the 2027 Notes and approximately $407.7 million principal amount of the 2037 Notes (the “Exchange Transactions”), in each case, pursuant to exemptions from registration under the Securities Act of 1933, as amended (the “Securities Act”), and the rules and regulations thereunder. The actual amounts of cash to be paid and shares of common stock to be issued are subject to adjustment during a one-day measurement period ending November 20, 2020, which may be extended upon certain events, and could vary substantially depending on changes in the trading price of the common stock during such period.

Following the closing of the Exchange Transactions, $222.4 million in aggregate principal amount of 2025 Notes will remain outstanding, $512.0 million in aggregate principal amount of 2027 Notes will remain outstanding and $278.6 million in aggregate principal amount of 2037 Notes will remain outstanding, in each case, with their terms unchanged.  The Exchange Transactions are expected to close concurrently on or about December 1, 2020, subject to customary closing conditions. The New Notes will represent senior subordinated obligations of Microchip that will be subordinated to Microchip’s senior debt and will pay interest semi-annually in arrears on each May 15 and November 15, commencing on May 15, 2021, at a rate of 0.125% per annum.  The New Notes will mature on November 15, 2024, unless earlier converted, redeemed or repurchased.  Prior to the close of business on the business day immediately preceding August 15, 2024, the New Notes will be convertible at the option of holders only upon the satisfaction of certain conditions and during certain periods.  On or after August 15, 2024 until close of business on the second scheduled trading day preceding maturity, the New Notes will be convertible at the option of the holders at any time regardless of these conditions. The New Notes will be convertible into cash, shares of Microchip’s common stock or a combination of cash and shares of Microchip’s common stock, at Microchip’s election.  The initial conversion rate of the New Notes will be determined using a conversion premium of approximately 40% above the 10b-18 volume weighted average price per share of Microchip’s common stock during a one-day measurement period ending November 20, 2020 (the “reference price”), which may be extended upon certain events, and will be subject to customary anti-dilution adjustments.  On or after November 20, 2022, Microchip may redeem for cash all or any portion of the New Notes if the last reported sale price of Microchip’s common stock has been at least 130% of the conversion price for the New Notes for at least 20 trading days during any 30 consecutive trading day period.

If Microchip undergoes a fundamental change (as defined in the indenture governing the New Notes), holders may require Microchip to purchase for cash all or part of their New Notes at a purchase price equal to 100% of the principal amount of the New Notes to be purchased, plus accrued and unpaid interest, if any, up to, but excluding, the fundamental change repurchase date.  In addition, if certain make-whole fundamental changes occur or Microchip calls the New Notes for redemption, Microchip will, in certain circumstances, increase the conversion rate for any New Notes converted in connection with such make-whole fundamental change or redemption.

Microchip will not receive any cash proceeds from the Exchange Transactions. In exchange for issuing, delivering and paying, as applicable, the New Notes, shares of Microchip’s common stock and cash pursuant to the Exchange Transactions, Microchip will receive and cancel the exchanged Existing Notes. In connection with the exchange agreements, Microchip entered into capped call transactions with certain dealers (the “option counterparties”). The capped call transactions are expected generally to reduce the potential dilution to Microchip’s common stock upon any conversion of New Notes and/or offset any cash payments Microchip is required to make in excess of the principal amount of converted New Notes, as the case may be, in each case upon conversion of the New Notes.  The strike price of the capped call transactions is set at approximately 40% above the reference price, subject to a cap price of 75% above the reference price.  Microchip expects to pay approximately $32.7 million for the cost of the capped call transactions.

In connection with establishing their initial hedge positions in respect of the capped call transactions, Microchip expects that the option counterparties will purchase shares of Microchip’s common stock and/or enter into various derivative transactions with respect to Microchip’s common stock concurrently with the execution of the exchange and/or during (and/or shortly after) the one-day measurement period described above.  In addition, in the event of certain market disruptions, the period during which the option counterparties will engage in such activities may be extended by up to five business days, in which case Microchip will correspondingly postpone the closing date of the Exchange Transactions.   This activity could increase (or reduce the size of any decrease in) the market price of common stock or the New Notes at that time.

In addition, the option counterparties may modify their hedge positions by entering into or unwinding various derivative transactions with respect to Microchip’s common stock and/or purchasing or selling Microchip’s common stock or other securities in secondary market transactions following the execution of the exchange and prior to the maturity of the New Notes (and are likely to do so during any observation period related to a conversion of the New Notes or following any redemption or repurchase of the New Notes by the Company).  This activity could also cause or avoid an increase or a decrease in the market price of common stock or the New Notes, which could affect the value of the shares of common stock that holders of the New Notes will receive upon conversion of the New Notes.

The New Notes, any shares of common stock issued in the Exchange Transactions and any shares issuable upon conversion of the New Notes have not been registered under the Securities Act or under any state securities laws and may not be offered or sold without registration under, or an applicable exemption from, the registration requirements. This announcement does not constitute an offer to sell, nor is it a solicitation of an offer to buy, these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any state or any jurisdiction.


Forward Looking Statements:

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the planned offering. Words such as “anticipates,” “estimates,” “expects,” “projects,” “forecasts,” “intends,” “plans,” “will,” “believes” and words and terms of similar substance used in connection with any discussion identify forward-looking statements. These forward-looking statements are based on management’s current expectations and beliefs about future events and are inherently susceptible to uncertainty and changes in circumstances. Except as required by law, Microchip is under no obligation to, and expressly disclaims any obligation to, update or alter any forward-looking statements whether as a result of such changes, new information, subsequent events or otherwise. With respect to the Exchange Transactions, such uncertainties and circumstances include whether Microchip will consummate the Exchange Transactions, the actual closing date of the Exchange Transactions, the initial conversion price of the New Notes and the hedging activity of the option counterparties and the impact such activity may have on Microchip’s common stock. Various factors could also adversely affect Microchip’s operations, business or financial results in the future and cause Microchip’s actual results to differ materially from those contained in the forward-looking statements, including those factors discussed in detail in the “Risk Factors” sections contained in Microchip’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2020 filed with the Securities and Exchange Commission.


About Microchip:

Microchip Technology Incorporated is a leading provider of smart, connected and secure embedded control solutions.  Its easy-to-use development tools and comprehensive product portfolio enable customers to create optimal designs, which reduce risk while lowering total system cost and time to market.  The company’s solutions serve more than 120,000 customers across the industrial, automotive, consumer, aerospace and defense, communications and computing markets.  Headquartered in Chandler, Arizona, Microchip offers outstanding technical support along with dependable delivery and quality.  For more information, visit the Microchip website at www.microchip.com.

Note: The Microchip name and logo are registered trademarks of Microchip Technology Inc. in the USA and other countries.

INVESTOR RELATIONS CONTACT:

J. Eric Bjornholt – CFO
(480) 792-7804 



Posted on

SpartanNash Declares Quarterly Cash Dividend

SpartanNash Declares Quarterly Cash Dividend

GRAND RAPIDS, Mich.–(BUSINESS WIRE)–
SpartanNash Company (Nasdaq: SPTN) (“SpartanNash” or the “Company”) today announced that its Board of Directors has approved a quarterly cash dividend of $0.1925 per common share. The dividend will be paid on December 31, 2020 to shareholders of record as of the close of business on December 10, 2020. As of November 18, 2020, there were 35,863,253 common shares outstanding.

About SpartanNash

SpartanNash (Nasdaq: SPTN) is a Fortune 400 company whose core businesses include distributing grocery products to a diverse group of independent and chain retailers, its corporate-owned retail stores and U.S. military commissaries and exchanges; as well as operating a premier fresh produce distribution network. SpartanNash serves customer locations in all 50 states and the District of Columbia, Europe, Cuba, Puerto Rico, Honduras, Bahrain, Djibouti and Egypt. SpartanNash currently operates 156 supermarkets, primarily under the banners of Family Fare, Martin’s Super Markets, D&W Fresh Market, VG’s Grocery and Dan’s Supermarket. Through its MDV military division, SpartanNash is a leading distributor of grocery products to U.S. military commissaries.

Investor Contacts:

Mark Shamber

Chief Financial Officer and Executive Vice President

(616) 878-8023

Chris Mandeville

Managing Director, ICR

(203) 682-8304

Media Contact:

Meredith Gremel

Vice President Corporate Affairs and Communications

(616) 878-2830

KEYWORDS: Michigan United States North America

INDUSTRY KEYWORDS: Supply Chain Management Supermarket Retail Food/Beverage

MEDIA:

Posted on

Antengene Corporation, an Innovative Cancer Biotech Company, is Listed on the Main Board of the Hong Kong Stock Exchange

PR Newswire

HONG KONG, Nov. 20, 2020 /PRNewswire/ — Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK), a leader in discovery, development and commercialization of innovative cancer medicines, today announced that the company was officially listed and it’s shares commenced trading on the Main Board of The Stock Exchange.

Antengene offered 154,153,500 shares in its global offering at a final price of HK$18.08 per share. The net proceeds from the global offering, after deducting underwriting fees and commissions paid and payable in connection with the global offering and estimated expenses, are estimated to be approximately HK$2,635,9 million. The company’s Hong Kong public offering was significantly oversubscribed, with valid applications received representing approximately 246.76 times the total number of offer shares initially available for subscription, and the international offering oversubscribed by 13.5 times. The final number of offer shares under the Hong Kong public offering and the international offering was 77,077,000 and 77,076,500, respectively, each representing approximately 50% of the total number of offer shares initially available for subscription under the global offering prior to the exercise of any over-allotment option.

Antengene is an integrated and innovative cancer biotech company. Based on a differentiated platform that focuses on a combination and complementary R&D strategy, the company discovers, develops and commercializes synergistic first-in-class, only-in-class and best-in-class cancer therapies that unlock the full therapeutic potential of its drug candidates. Currently, Antengene has built an innovative pipeline of 12 assets . One of the core products, ATG-010 (selinexor, US trade name XPOVIO®), is the first and only selective inhibitor of nuclear export (SINE) of its kind, which can promote the accumulation of tumor suppressor protein in the cell nucleus and selectively induce apoptosis in cancer cells. The product has been approved by the FDA for the treatment of patients with relapsed refractory multiple myeloma and diffuse large B-cell lymphoma, and its Phase III clinical trial for the treatment of patients with liposarcoma met its primary study endpoint reporting a significantly prolonged progression-free survival (PFS). Currently, Antengene is conducting a Phase II clinical trial of ATG-010 (selinexor) for relapsed refractory multiple myeloma and relapsed refractory diffuse large B-cell lymphoma in China, and plans to submit new drug applications for ATG-010 (selinexor) in the Chinese mainland, Hong Kong China, Taiwan China, Australia, Singapore, South Korea by 2021. In addition to ATG-010, two other active SINE compounds in the pipeline — ATG-016 (eltanexor) and ATG-527 (verdinexor), are in clinical trials addressing unmet medical needs across several diseases.  

ATG-008 (onatasertib), a second-generation orally available dual-target mTORC1/2 inhibitor, has the potential to overcome the drawbacks of drug resistance of traditional mTORC1 inhibitors. Currently, Antengene is conducting single agent and combination trials across several advanced solid tumors. ATG-019 (KPT-9274) has the potential to be a first-in-class orally available dual-target PAK4 and NAMPT inhibitor for the treatment of non-Hodgkin’s lymphoma (NHL) and advanced solid tumors. ATG-017 (AZD0364) is a potent and selective ERK1/2 inhibitor with best-in-class potential for the treatment of various hematological malignancies and solid tumors caused by abnormalities in the RAS/MAPK pathway.

In addition, Antengene is working on early stage preclinical research and early drug development for several innovative-target drugs in the small molecule, monoclonal and bispecific antibody fields, including ATG-101 (PD-L1/4-1BB bispecific antibody), ATG-018 (ATR inhibitor), ATG-022 (Claudin 18.2 monoclonal antibody) and ATG-012 (KRAS inhibitor), which are currently proceeding rapidly to IND stage .

Dr. Jay MEI, Founder, Chairman and CEO of Antengene, has more than 25 years of global experience in clinical R&D of oncology therapies, with a focus on clinical R&D of oncology drugs. Other management members have distinguished achievements in drug research, clinical development, commercialization, financing and investment. Since its inception, Antengene has attracted leading industry investors including strategic investors such as Celgene, WuXi AppTec and Tigermed; and financial investors including Fidelity, GIC, BlackRock, Hillhouse Capital, Boyu Capital, FountainVest and Qiming Ventures Partners. In addition, Fidelity, GIC, BlackRock, Boyu Capital, Cormorant, Hillhouse Capital, Sequoia Capital, Morning Hill Capital, Laurion Capital Master Fund and Octagon Investments are cornerstone investors of the company’s global offering.

Dr. Jay MEI, Founder, Chairman and CEO of Antengene, stated, “Today is a major milestone in Antengene’s history. The successful listing of Antengene in the Hong Kong stock market, demonstrates global investors’ recognition of our strategic model, growth potential, management team and product pipeline; we are very proud of our success, and appreciate their trust and support of Antengene. Based on this new starting point, we will seize the historical opportunity to advance of the global development of innovative drugs, seize the most cutting-edge research and development hotspots through differentiated development strategies, and constantly discover, develop and commercialize innovative cancer therapies with new action mechanisms of action, so as to solve the unmet clinical needs of patients in APAC and across the world.”

The funds raised will mainly be used to advance our 9 ongoing clinical trials and our other clinical stage product pipeline assets, our 6 preclinical assets in discovery, and prepare to launch selinexor across China and the APAC region. In addition, the funds will also be used for pipeline expansion and talent recruitment to further consolidate the company’s R&D foundation, accelerate clinical research, and benefit cancer patients across the world.

About Antengene Corporation Limited

Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK) is a biopharmaceutical company with an integrated drug discovery and clinical development approach, anchored in Asia Pacific with a global footprint. Antengene aims to provide the most advanced anti-cancer drugs to patients in China, the Asia Pacific Region and around the world. Since its official start in April 2017, Antengene has built a pipeline of 12 clinical and pre-clinical stage assets, obtained 9 IND approvals and has 9 ongoing cross-regional clinical trials in Asia Pacific. At Antengene, we focus on developing drug candidates with novel MoAs and first-in-class/best-in-class potential to address significant unmet medical needs. The vision of Antengene is to “Treat Patients Beyond Borders” through research, development and commercialization of first-in-class/best-in-class therapeutics.

Cision View original content:http://www.prnewswire.com/news-releases/antengene-corporation-an-innovative-cancer-biotech-company-is-listed-on-the-main-board-of-the-hong-kong-stock-exchange-301178030.html

SOURCE Antengene Corporation Limited

Posted on

Superior Drilling Products, Inc. Receives Notice of Noncompliance from NYSE American

Superior Drilling Products, Inc. Receives Notice of Noncompliance from NYSE American

VERNAL, Utah–(BUSINESS WIRE)–Superior Drilling Products, Inc. (NYSE American: SDPI) (“SDP” or the “Company”), an innovator and manufacturer of drilling tool technologies, today announced that on November 18, 2020, the Company received notification from the NYSE American LLC (the “NYSE American”) that it had not met compliance standards of Section 1003(a)(iii) as a result of stockholders’ equity falling below $6.0 million and having reported losses in its five most recent fiscal years ended December 31, 2019. Stockholders’ equity was approximately $4.7 million as of September 30, 2020.

The Company will evaluate all available options to regain compliance with the continued listing standards by the required date of May 18, 2022. SDP then intends to submit a plan for regaining compliance to the NYSE American by the required submission date of December 18, 2020. If the NYSE American accepts the plan, the Company will be subject to ongoing periodic reviews, including quarterly monitoring, for compliance with the plan.

About Superior Drilling Products, Inc.

Superior Drilling Products, Inc. is an innovative, cutting-edge drilling tool technology company providing cost saving solutions that drive production efficiencies for the oil and natural gas drilling industry. The Company designs, manufactures, repairs and sells drilling tools. SDP drilling solutions include the patented Drill-N-Ream® well bore conditioning tool and the patented Strider™ oscillation system technology. In addition, SDP is a manufacturer and refurbisher of PDC (polycrystalline diamond compact) drill bits for a leading oil field service company. SDP operates a state-of-the-art drill tool fabrication facility, where it manufactures its solutions for the drilling industry, as well as customers’ custom products. The Company’s strategy for growth is to leverage its expertise in drill tool technology and innovative, precision machining in order to broaden its product offerings and solutions for the oil and gas industry.

Additional information about the Company can be found at: www.sdpi.com.

Safe Harbor Regarding Forward Looking Statements

This news release contains forward-looking statements and information that are subject to a number of risks and uncertainties, many of which are beyond our control. All statements, other than statements of historical fact included in this release, including, without limitations, the continued impact of COVID-19 on the business, the Company’s strategy, future operations, success at developing future tools, the Company’s effectiveness at executing its business strategy and plans, financial position, estimated revenue and losses, projected costs, prospects, plans and objectives of management, and ability to outperform are forward-looking statements. The use of words “could,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “may,” “continue,” “predict,” “potential,” “project”, “forecast,” “should” or “plan, and similar expressions are intended to identify forward-looking statements, although not all forward -looking statements contain such identifying words. These statements reflect the beliefs and expectations of the Company and are subject to risks and uncertainties that may cause actual results to differ materially. These risks and uncertainties include, among other factors, the duration of the COVID-19 pandemic and related impact on the oil and natural gas industry, the effectiveness of success at expansion in the Middle East, options available for market channels in North America, the deferral of the commercialization of the Strider technology, the success of the Company’s business strategy and prospects for growth; our ability to maintain the listing of our common stock on the NYSE American; the market success of the Company’s specialized tools, effectiveness of its sales efforts, its cash flow and liquidity; financial projections and actual operating results; the amount, nature and timing of capital expenditures; the availability and terms of capital; competition and government regulations; and general economic conditions. These and other factors could adversely affect the outcome and financial effects of the Company’s plans and described herein. The Company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.

For more information, contact investor relations:

Deborah K. Pawlowski

Kei Advisors LLC

(716) 843-3908

[email protected]

 

KEYWORDS: Utah United States North America

INDUSTRY KEYWORDS: Oil/Gas Natural Resources Other Manufacturing Finance Energy Professional Services Mining/Minerals Manufacturing

MEDIA:

Logo
Logo
Posted on

MEDIA ALERT: Equinix to Speak at Upcoming Investor Conferences

PR Newswire

REDWOOD CITY, Calif., Nov. 20, 2020 /PRNewswire/ — Equinix, Inc. (Nasdaq: EQIX), the world’s digital infrastructure company, today announced that its executives will attend four upcoming investor conferences:

  • Bank of America 2020 Global Data Center Virtual Conference on Wednesday, November 25. Jeremy Deutsch, President, Asia-Pacific, and Katrina Rymill, VP of Investor Relations & Sustainability, will present at 5:00 p.m. PST.

  • 2020 Wells Fargo TMT Summit on Tuesday, December 1. Steve Madden, VP of Segment Marketing and Katrina Rymill, VP of Investor Relations & Sustainability, will present at 12:20 p.m. PST.

  • NASDAQ 43rd Investor Conference on Wednesday, December 2. Keith Taylor, Chief Financial Officer, will present at 7:00 a.m. PST.

  • Barclays 2020 Global Technology, Media and Telecommunications Virtual Conference on Thursday, December 10. Jon Lin, President, Americas, will present at 7:00 a.m. PST.

The presentations will be made available via webcast on the Investor Relations section of the Equinix website at www.equinix.com/investors.

About Equinix


Equinix
 (Nasdaq: EQIX) is the world’s digital infrastructure company, enabling digital leaders to harness a trusted platform to bring together and interconnect the foundational infrastructure that powers their success. Equinix enables today’s businesses to access all the right places, partners and possibilities they need to accelerate advantage. With Equinix, they can scale with agility, speed the launch of digital services, deliver world-class experiences and multiply their value.

 

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/media-alert-equinix-to-speak-at-upcoming-investor-conferences-301177942.html

SOURCE Equinix, Inc.

Posted on

Princess Cruises Extends Pause of Global Ship Operations into 2021

PR Newswire

SANTA CLARITA, Calif., Nov. 20, 2020 /PRNewswire/ — In response to the U.S. Centers for Disease Control and Prevention (CDC) “Framework for Conditional Sailing Order” pertaining to resumption of U.S. cruise operations, Princess Cruises is extending its pause in global operations to allow time for the estimated preparation needed for completing required activities prior to sailing and taking into consideration the temporary seven-day cap on itineraries that call at a U.S. port. The cruise operations impacted include the following:

  • All cruises sailing through March 31, 2021
  • All cruises longer than seven days sailing in and out of United States ports through November 1, 2021

Additionally, due to the uncertainty about when international travel restrictions might be lifted, Princess Cruises is extending its pause in operations for cruises departing in and out of Japan through June 25, 2021.

“We are focused on preparing our ships to meet the CDC health and safety requirements for our eventual return to service,” said Jan Swartz, president of Princess Cruises. “We also appreciate the continued support we have received from our guests, partners and travel advisors, reinforcing for all of us why we do what we do.”

Guests currently booked on these cancelled voyages will have the option to receive a refundable Future Cruise Credit (FCC) equivalent to 100% of the cruise fare paid plus an additional non-refundable bonus FCC equal to 25% of the cruise fare.

To receive the above FCCs, no action is required by the guest or their travel advisor.

Alternatively, guests can request a full refund for all monies paid on their booking through this online form. Requests must be received by December 31, 2020 or guests will be registered for the Future Cruise Credit option.

Princess will protect travel advisor commissions on bookings for cancelled cruises that were paid in full in recognition of the critical role they play in the cruise line’s business and success.

The most current information and instructions for booked guests affected by these cancellations, and more information on FCCs and refunds, can be found online at Information on Impacted & Cancelled Cruises.


About Princess Cruises

:

One of the best-known names in cruising, Princess Cruises is an international premium cruise line and tour company operating a fleet of 15 modern cruise ships, carrying two million guests each year to 380 destinations around the globe, including the Caribbean, Alaska, Panama Canal, Mexican Riviera, Europe, South America, Australia/New Zealand, the South Pacific, Hawaii, Asia, Canada/New England, Antarctica and World Cruises. A team of professional destination experts have curated 170 itineraries, ranging in length from three to 111 days and Princess Cruises is continuously recognized as “Best Cruise Line for Itineraries.” In 2017 Princess Cruises, with parent company Carnival Corporation, introduced MedallionClass Vacations enabled by the OceanMedallion, the vacation industry’s most advanced wearable device, provided free to each guest sailing on a MedallionClass ship. The award-winning innovation offers the fastest way to an effortless personalized vacation giving guests more time to do the things they love most. The company is part of Carnival Corporation & plc (NYSE/LSE: CCL; NYSE:CUK).

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/princess-cruises-extends-pause-of-global-ship-operations-into-2021-301177874.html

SOURCE Princess Cruises

Posted on

Fuling Global Shareholders Approve Going Private Transaction

PR Newswire

WENLING, China, Nov. 20, 2020 /PRNewswire/ — Fuling Global Inc. (Nasdaq: FORK) (“Fuling Global” or the “Company”), a manufacturer and distributor of mainly environmentally-friendly plastic and paper foodservice disposable products, announced that at an extraordinary general meeting of shareholders (the “EGM”) held today, the Company’s shareholders voted in favor of, among other things, the proposal to authorize and approve (i) the previously announced agreement and plan of merger dated as of September 1, 2020 (the “Merger Agreement”), by and among the Company, Fuling ParentCo Inc., an exempted company with limited liability incorporated under the laws of the Cayman Islands (“Parent”) and Fuling MergerCo Inc., an exempted company with limited liability incorporated under the laws of the Cayman Islands and a wholly-owned subsidiary of Parent (“Merger Sub”); (ii) the plan of merger required to be filed with the Registrar of Companies of the Cayman Islands (the “Plan of Merger”), pursuant to which Merger Sub will merge with and into the Company, with the Company continuing as the surviving company and becoming a wholly owned subsidiary of the Parent (the “Merger”); and (iii) any and all transactions contemplated by the Merger Agreement and the Plan of Merger, including the Merger.

Six registered shareholders entitled to vote were present at the EGM by proxy or by their duly authorized representatives representing 72.71% in nominal value of the total issued voting shares in the Company. As such, a quorum was present. The Merger Agreement, the Plan of Merger and the transactions contemplated thereby, including the Merger, were approved by approximately 95.25% of the ordinary shares present and voting in person or by proxy at the EGM.

The parties currently expect to complete the Merger as soon as practicable, subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement. Upon completion of the Merger, the Company will become a privately held company, and its ordinary shares will no longer be listed on the NASDAQ Capital Market.

About Fuling Global Inc.

Fuling Global manufactures and distributes mainly environmentally-friendly disposable serviceware for the foodservice industry, with six precision manufacturing facilities in the U.S., Mexico, Indonesia and China. The Company’s plastic and paper serviceware products include disposable cutlery, drinking straws, cups, plates and other plastic and paper products and are used by more than one hundred customers, including some of the world’s most notable quick-service restaurants and retailers, primarily in the U.S., China, Canada and European countries. More information about the Company can be found at: http://ir.fulingglobal.com/.

Safe Harbor Statement

This press release contains statements that express the Company’s current opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results and therefore are, or may be deemed to be, “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 (the “Act”). These forward-looking statements can be identified by terminology such as “if,” “will, “”expected” and similar statements. Forward-looking statements involve inherent risks, uncertainties and assumptions and other factors that could cause actual results to differ materially from those contained in any such statements. Risks, uncertainties and assumptions include, but are not limited to the following: uncertainties as to the expected benefits and costs of the proposed Merger, the expected timing of the completion of the Merger, and the parties’ ability to complete the Merger considering the various closing conditions; the possibility that financing may not be available; the possibility that various closing conditions for the transaction may not be satisfied or waived; and other risks and uncertainties discussed in documents filed with the SEC by the Company, as well as the Schedule 13E-3 transaction statement and the proxy statement filed by the Company. These forward-looking statements reflect the Company’s expectations as of the date of this press release. You should not rely upon these forward-looking statements as predictions of future events. The Company does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

Cision View original content:http://www.prnewswire.com/news-releases/fuling-global-shareholders-approve-going-private-transaction-301177805.html

SOURCE Fuling Global Inc.

Posted on

Stealth BioTherapeutics Announces $3.2 Million Registered Direct Offering

PR Newswire

BOSTON, Nov. 20, 2020 /PRNewswire/ — Stealth BioTherapeutics Corp (Nasdaq: MITO) (“Stealth” or the “Company”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that it has entered into securities purchase agreements with several institutional investors to purchase 2,844,446 of its American Depositary Shares (“ADSs”), each ADS representing 12 ordinary shares of the Company, in a registered direct offering. The purchase price for one ADS is $1.125.

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

The gross proceeds from this offering are expected to be approximately $3.2 million. This offering is expected to close on or about November 24, 2020, subject to the satisfaction of customary closing conditions.

The ADSs described above are being offered pursuant to a “shelf” registration statement (File No. 333-237542) filed with the Securities and Exchange Commission (SEC) and declared effective on April 10, 2020. The ADSs may be offered only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A prospectus supplement and the accompanying prospectus relating to the offering of the ADSs will be filed with the SEC. Electronic copies of the prospectus supplement and the accompanying prospectus relating to the offering of ADSs may be obtained, when available, on the SEC’s website at http://www.sec.gov or by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by e-mail: [email protected] or by telephone: (646) 975-6996.

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

About Stealth

We are a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction. Mitochondria, found in nearly every cell in the body, are the body’s main source of energy production and are critical for normal organ function.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking include statements about the anticipated completion of the registered direct offering. Statements that are not historical facts, including statements about Stealth BioTherapeutics’ beliefs, plans and expectations, are forward-looking statements. The words “anticipate,” “expect,” “hope,” “plan,” “potential,” “possible,” “will,” “believe,” “estimate,” “intend,” “may,” “predict,” “project,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Stealth BioTherapeutics may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements as a result of known and unknown risks, uncertainties and other important factors, including: Stealth BioTherapeutics’ ability to obtain additional funding and to continue as a going concern; the impact of the COVID-19 pandemic; the ability to successfully demonstrate the efficacy and safety of Stealth BioTherapeutics’ product candidates and future product candidates; the preclinical and clinical results for Stealth BioTherapeutics’ product candidates, which may not support further development and marketing approval; the potential advantages of Stealth BioTherapeutics’ product candidates; the content and timing of decisions made by the U.S. FDA, the EMA or other regulatory authorities, investigational review boards at clinical trial sites and publication review bodies, which may affect the initiation, timing and progress of preclinical studies and clinical trials of Stealth BioTherapeutics’ product candidates; Stealth BioTherapeutics’ ability to obtain and maintain requisite regulatory approvals and to enroll patients in its planned clinical trials; unplanned cash requirements and expenditures; competitive factors; Stealth BioTherapeutics’ ability to obtain, maintain and enforce patent and other intellectual property protection for any product candidates it is developing; and general economic and market conditions. These and other risks are described in greater detail under the caption “Risk Factors” included in the Stealth BioTherapeutics’ most recent Annual Report on Form 20-F filed with the SEC, as well as in any future filings with the SEC. Forward-looking statements represent management’s current expectations and are inherently uncertain. Except as required by law, Stealth BioTherapeutics does not undertake any obligation to update forward-looking statements made by us to reflect subsequent events or circumstances.

Investor Relations 

Stern Investor Relations
Janhavi Mohite, 212-362-1200
[email protected]

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/stealth-biotherapeutics-announces-3-2-million-registered-direct-offering-301177823.html

SOURCE Stealth BioTherapeutics Inc.

Posted on

Centene Corporation To Host Virtual 2021 Financial Guidance And Investor Meeting On December 18, 2020

PR Newswire

ST. LOUIS, Nov. 20, 2020 /PRNewswire/ — Centene Corporation (NYSE: CNC) will host its 2021 Financial Guidance and Investor Meeting, in a virtual format, on Friday, December 18th, 2020. Michael F. Neidorff, Chairman, President and Chief Executive Officer, and Jeffrey A. Schwaneke, Executive Vice President and Chief Financial Officer, of Centene Corporation will host the virtual meeting, which will be streamed live on the Company’s website at www.centene.com, under the Investors section.

Additional details for the virtual meeting, as well as instructions for institutional investors and analysts to enable the Question & Answer component, to follow.

About Centene Corporation
Centene Corporation, a Fortune 50 company, is a leading multi-national healthcare enterprise that is committed to helping people live healthier lives. The Company takes a local approach – with local brands and local teams – to provide fully integrated, high-quality, and cost-effective services to government-sponsored and commercial healthcare programs, focusing on under-insured and uninsured individuals. Centene offers affordable and high-quality products to nearly 1 in 15 individuals across the nation, including Medicaid and Medicare members (including Medicare Prescription Drug Plans) as well as individuals and families served by the Health Insurance Marketplace, the TRICARE program, and individuals in correctional facilities. The Company also serves several international markets, and contracts with other healthcare and commercial organizations to provide a variety of specialty services focused on treating the whole person. Centene focuses on long-term growth and the development of its people, systems and capabilities so that it can better serve its members, providers, local communities, and government partners.

Centene uses its investor relations website to publish important information about the company, including information that may be deemed material to investors. Financial and other information about Centene is routinely posted and is accessible on Centene’s investor relations website, http://www.centene.com/investors.           

 

Cision View original content:http://www.prnewswire.com/news-releases/centene-corporation-to-host-virtual-2021-financial-guidance-and-investor-meeting-on-december-18-2020-301177916.html

SOURCE Centene Corporation